222 filings
Page 5 of 12
8-K
rvm0d8xiqv
12 Feb 21
VistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021
4:05pm
8-K
lfe1feu8l7 duy82r9
2 Feb 21
Departure of Directors or Certain Officers
5:13pm
8-K
rxdl7dtl96o9m1apq1dt
6 Jan 21
Other Events
4:05pm
8-K
p4lno1no7jdu2yz9a
22 Dec 20
VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering
4:17pm
8-K
g9atyz k5rdlftsxfv
1 Dec 20
Other Events
4:24pm
8-K
tibqw1546yh ckhnc80h
16 Nov 20
VistaGen Therapeutics Reports Fiscal 2021 Second Quarter Financial Results and Provides Highlights on its CNS Pipeline and Business Progress
12:00am
8-K
lg1rurdalq0 or4mx
13 Oct 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:06pm
8-K
tr1eeff r5k
18 Sep 20
2020 Virtual Annual Meeting of Stockholders
9:14am
8-K
zn1f9viy 1o7o
14 Aug 20
VistaGen Therapeutics Reports Fiscal 2021 First Quarter Financial Results and Highlights CNS Pipeline and Business Progress
5:24pm
8-K
8o5syw417
5 Aug 20
VistaGen Therapeutics Announces Pricing of $12.5 Million Underwritten Public Offering of Common Stock
9:56pm
8-K
ye3b302u9pot04
24 Jul 20
Regulation FD Disclosure
6:03am
8-K
379s1c0 mbp3vfe
30 Jun 20
VistaGen Therapeutics Reports Fiscal Year 2020 Results and Provides CNS Pipeline Update
4:16pm
8-K
9b7c11z24 zktv3k3td
26 Jun 20
Collaboration intended to support Phase 3 development and commercialization of PH94B in key Asian markets
5:27pm
8-K
rm6z8e8e 1qgp7
1 Jun 20
VistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS Conditions
4:53pm
8-K
gc729w qfunxha
18 May 20
The Proposed Phase 2A Open-label Study will be Conducted in New York City
5:15pm
8-K
69pok
28 Apr 20
VistaGen Expands PH94B Clinical Development to Include Adjustment Disorder Related to COVID-19
4:32pm
8-K
cr6f7 kljftcaw7x2n2
27 Apr 20
Entry into a Material Definitive Agreement
5:16pm
8-K
2rk7i5j33r110vwbn
3 Apr 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:15pm
8-K
kygafb6d
26 Mar 20
VistaGen Therapeutics Announces Common Stock Purchase Agreement for up to $10.25 Million
7:05am
8-K
4p32r6
21 Feb 20
VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder
12:00am